Tepotinib had durable clinical activity in Japanese patients with MET exon 14 skipping NSCLC, identified by liquid and/or tissue biopsy, with a response rate of 60.0% (n = 9/15) by IRC, a median DOR that was not reached, and a median PFS of 11.0 months. Here, MET is linked to non-small cell lung carcinoma.